|
||||||||||||||||||||||||||||||||||||||||||||||||||
![]()
CAS号:22260-51-1
|
英文名称:Bromocriptine mesylate
分子式
C33H44BrN5O8S
分子量
751
EINECS号
244-881-1
MDL
MFCD09028065
Smiles
InChIKey
乙二醇化学百科
基本信息
物化性质
安全信息
生产及用途
甲磺酸溴隐亭最早由诺华公司开发,主要用于抗震颤麻痹,抑制生理性泌乳和治疗催乳激素过高引起的经前期综合征、肢端肥大症、女性不育症和亨丁顿舞蹈病。临床用于治疗帕金森病,与催乳素有关的生殖系统功能异常,如闭经、溢乳症、经前综合征、产褥期乳腺炎、纤维囊性乳腺瘤、男性阳痿或性欲减退,还可用于垂体腺瘤等。甲磺酸溴隐亭快速释放的口服制剂辅助用于Ⅱ型糖尿病的治疗,该药2009年5月获得FDA批准。本品又称溴麦亭、溴化麦角隐亭、溴克丁、麦角克碱、麦角环肽、抑乳停、甲磺酸溴隐亭,是麦角生物碱的半合成衍生物,能特异地兴奋中枢多巴胺受体,对其他受体有拮抗作用。无麦角类的收缩子宫和血管作用。可抑制PRL、LH的分泌,激活脑内新纹状体的多巴胺受体,控制震颤麻痹综合征;通过中枢或外周的作用松弛血管平滑肌,减低交感神经兴奋性,进而使血压下降,脉率不增加。适用于治疗高泌乳素血症及泌乳素瘤,或作为泌乳素瘤的术前准备或术后治疗;亦用于治疗垂体生长激素瘤、巨人症及肢端肥大症;或用于垂体促皮质素瘤及库欣(Cushing)病合并血糖升高者的治疗。可用于治疗多囊卵巢综合征,对排卵功能障碍性不孕症有效。对乳腺增生、回乳、月经紊乱、经前紧张综合征、肝性脑病、糖尿病、特发性水肿、垂体性甲亢及甲状腺功能减退症均有一定效果。 1)溴隐亭的合成 将α-麦角隐亭12g(20.8mmoL)和二氯甲烷120mL加入反应瓶中,搅拌溶清后依次加入5,5-二溴巴比妥酸3.69g(12.9mmoL)、33%氢溴酸的冰乙酸溶液0.2mL,控温25~30℃反应5~6h,过滤,滤液依次用1moL/L的硫代硫酸钠(30mL),5%的碳酸氢钠溶液(30mL),20%氯化钠溶液(30mL)洗涤。有机相用无水硫酸镁干燥,过滤,并加入硅胶36g浓缩将溶剂完全拉干。柱层析:流动相先为二氯甲烷,后为V(二氯甲烷)∶V(丙酮)=6∶1的混合溶液。得10.6g溴隐亭,收率78%。 2)甲磺酸溴隐亭的合成 将溴隐亭6.0g用二氯甲烷120mL溶清后加入2-丁酮200mL,控制内温20~30℃,加入甲磺酸1.14g,生成结晶型沉淀,搅拌1h。滤出固体,用2-丁酮30mL洗涤,干燥得6.13g甲磺酸溴隐亭,收率86%。 Bromocriptine mesylate 是一种有效的多巴胺 D2/D3 受体激动剂,结合多巴胺 D2 受体,pKi 为 8.05±0.2。pKi: 8.05±0.2 (dopamine D2 receptor) Bromocriptine stimulates [ 35 S]-GTPγS binding at D2 dopamine receptor expressed in CHO cells with pEC 50 of 8.15±0.05. Bromocriptine also is a strong inhibitor of brain nitric oxide synthase. The ergot alkaloid Bromocriptine (BKT) is found to act as a strong inhibitor of purified neuronal nitric oxide synthase (NOS) (IC 50 =10±2 μM) whereas it is poorly active towards inducible macrophage NOS (IC 50 >100 μM) . Bromocriptine is found to inhibit the activity of at least one human cytochrome P450 enzyme. Bromocriptine is a potent inhibitor of CYP3A4 with a calculated IC 50 value for the interaction of 1.69 μM.
Bromocriptine mesylate (2 mg/kg, i.p.) is administered for 7 days in groups of mice in forced swimming test (FST) and tail suspension test (TST). Bromocriptine group shows significant anti-immobility action as compared to control. When Bromocriptine administered 30 min after the last dose of 7 days MPE treatment and subjected to FST, this dopaminergic agonist produces significant and dose dependent potentiation of anti-immobility action of MPE (200 mg/kg, p.o.) as compared to MPE treatment alone. Bromocriptine treatment group shows a significant reduction of immobility time as compared to control. Bromocriptine administration after 7 days pretreatment with MPE (100 and 200 mg/kg, p.o.) shows significant and dose dependent potentiation of anti-immobility action of MPE as compared to MPE treatment alone. Intracisternal administration of Bromocriptine decreases significantly the static mechanical allodynia (SMA) score compared to that of sham (saline-injected rats) and its effect lasted for 30 min. Intraperitoneal administration of Bromocriptine induces a significant, dose dependent (0.1 mg and 1 mg/kg) decrease in pain scores in CCI-IoN group when compared to sham and its effect lasted for 6 h. The highest dose induces the highest score decrease (P<0.01). Bromocriptine effect lasts for 20 min. Intraperitoneal administration of Bromocriptine induces a significant dose dependent decrease in SMA score in CCI-IoN+6-OHDA lesioned group compared to that of sham. Its effect lasts for 6 h.
类别 有毒物质毒性分级 中毒急性毒性 口服-小鼠 LD50: 2502 毫克/公斤; 静脉-大鼠 LD50: 10.5 毫克/公斤可燃性危险特性 热分解排出有毒氮氧化物,硫氧化物和溴化物烟雾储运特性 库房通风干燥低温灭火剂 水,干粉,二氧化碳,泡沫,沙土
上下游产品
上游产品共计:4个
下游产品共计:0个
相关产品
产品供应商
|
||||||||||||||||||||||||||||||||||||||||||||||||||